Breathing through bone drugs
How Merck's osteoporosis drug alendronate could be repurposed for COPD
Reversing or halting progressive airway damage is still the biggest challenge in COPD, but a study from Japan suggests a subclass of osteoporosis drugs could offer a new way to tackle the disease that takes advantage of the compounds' ability to suppress macrophages. The strategy capitalizes on new thinking that alveolar macrophages play a dominant pathological role in COPD, but some researchers question whether suppressing the cells will remove a key mechanism for preventing infection in the lungs.
In chronic obstructive pulmonary disease (COPD), the characteristic decrease in airflow is caused by inflammation, which causes the hallmark breakdown of elastin and destroys the integrity of the alveolar walls.
Although many types of immune cells infiltrate the airspace in COPD in response to injury, alveolar macrophages have recently been implicated as the main drivers of the disease. That is a shift from the previous dogma that neutrophils were the key contributors to COPD pathology, and that the role of macrophages was primarily to protect